Pemetrexed

DCTPepD ID  DCTPepD0025

Active Ingredients   Pemetrexed

Description  A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.

Synonyms  L-Glutamic Acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl); MTA; Multitargeted Antifolate; Pemfexy; Pemetrexed

Disease  Non-small cell lung cancer (NSCLC), Mesothelioma

Classification

  

Administered folate antagonist Amino acid and derivative

Structure Information


Molecular Formula  C20H21N5O6

Molecular Weight  427.4

Active Sequence  Not available

Sequence Length  Not available

Modification  Not available

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  (2S)-2-[[4-[2-(2-amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid

InChI  InChI=1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)/t13-/m0/s1

InChI_Key WBXPDJSOTKVWSJ-ZDUSSCGKSA-N

SMILES  O=C(O)[C@@H](NC(C1=CC=C(CCC2=CNC(N=C(N)N3)=C2C3=O)C=C1)=O)CCC(O)=O

External Codes


PubChem CID  135410875

DrugBank Accession Number  DB00642

NCI Thesaurus Code  C61614  

UNII  04Q9AIZ7NO   GSRS

CAS  137281-23-3



Drug approval


Drug indication
    Pemetrexed is indicated for use in patients with non-squamous non-small cell lung cancer (NSCLC), either in combination with pembrolizumab and platinum-based chemotherapy as initial treatment in metastatic disease where no EGFR or ALK genomic tumour aberrations exist, in combination with cisplatin as initial treatment for locally advanced or metastatic disease, as maintenance treatment for locally advanced or metastatic disease that has not progressed following four cycles of platinum-based chemotherapy, and for treatment of recurrent metastatic disease following prior chemotherapy.
Pemetrexed is also indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.

Drug Name Strength Dosage Form/Route Company Marketing Status Drug ID Approval year
Alimta eq 500mg base/vial Powder; Intravenous Lilly Prescription NDA: 021462 2004
Alimta eq 100mg base/vial Powder; Intravenous Lilly Prescription NDA: 021462 2004
Alimta 500mg Injectable; Injection Lilly Prescription NDA: 021677 2004
Pemetrexed 500mg Injectable; Injection Teva Pharms Usa Prescription ANDA: 090352 2019
Pemetrexed 500mg Injectable; Injection Mylan Labs Ltd Prescription ANDA: 203628 2019
Pemetrexed unknown Unknown Sun Pharm Inds Ltd None (Tentative Approval) ANDA: 205238 2019
Pemetrexed 100mg/4ml (25mg/ml) Solution; Intravenous Actavis Llc Prescription NDA: 208419 2020
Pemetrexed 500mg/20ml (25mg/ml) Solution; Intravenous Actavis Llc Prescription NDA: 208419 2020
Pemetrexed 1gm/40ml (25mg/ml) Solution; Intravenous Actavis Llc Prescription NDA: 208419 2020
Pemetrexed eq 100mg base/vial Powder; Intravenous Hospira Inc Prescription NDA: 208746 2022
Pemetrexed eq 500mg base/vial Powder; Intravenous Hospira Inc Prescription NDA: 208746 2022
Pemetrexed eq 1g base/vial Powder; Intravenous Hospira Inc Prescription NDA: 208746 2022
Pemetrexed 100mg Injectable; Injection Biocon Ltd Prescription ANDA: 208927 2018
Pemetrexed 500mg Injectable; Injection Biocon Ltd Prescription ANDA: 208927 2018
Pemetrexed 100mg Injectable; Injection Apotex Inc Prescription NDA: 210661 2018
Pemetrexed 500mg Injectable; Injection Apotex Inc Prescription NDA: 210661 2018
Pemetrexed 100mg/4ml (25mg/ml) Injectable; Injection Hospira Inc Prescription NDA: 214218 2022
Pemetrexed 500mg/20ml (25mg/ml) Injectable; Injection Hospira Inc Prescription NDA: 214218 2022
Pemetrexed 1g/40ml (25mg/ml) Injectable; Injection Hospira Inc Prescription NDA: 214218 2022
Pemetrexed 100mg/4ml (25mg/ml), Solution; Intravenous Accord Hlthcare Inc Prescription NDA: 214408 2022
Pemetrexed 500mg/20ml (25mg/ml) Solution; Intravenous Accord Hlthcare Inc Prescription NDA: 214408 2022
Pemetrexed 850mg/34ml (25mg/ml) Solution; Intravenous Accord Hlthcare Inc Prescription NDA: 214408 2022
Pemetrexed 1000mg/40ml (25mg/ml). Solution; Intravenous Accord Hlthcare Inc Prescription NDA: 214408 2022
Pemetrexed eq 100mg base/4ml (eq 25mg base/mg) Solution; Intravenous Sandoz Inc Prescription NDA: 214657 2022
Pemetrexed eq 500mg base/20ml (eq 25mg base/ml) Solution; Intravenous Sandoz Inc Prescription NDA: 214657 2022
Pemetrexed eq 1gm base/40ml (eq 25mg base/ml) Solution; Intravenous Sandoz Inc Prescription NDA: 214657 2022
Pemetrexed Disodium eq 100mg base/vial Powder; Intravenous Fresenius Kabi Usa Prescription ANDA: 090384 2022
Pemetrexed Disodium eq 500mg base/vial Powder; Intravenous Fresenius Kabi Usa Prescription ANDA: 090384 2022
Pemetrexed Disodium eq 750mg base/vial Powder; Intravenous Fresenius Kabi Usa Prescription ANDA: 090384 2022
Pemetrexed Disodium eq 1gm base/vial Powder; Intravenous Fresenius Kabi Usa Prescription ANDA: 090384 2022
Pemetrexed Disodium eq 100mg base/vial Powder; Intravenous Hospira Prescription ANDA: 202111 2022
Pemetrexed Disodium eq 500mg base/vial Powder; Intravenous Hospira Prescription ANDA: 202111 2022
Pemetrexed Disodium eq 1gm base/vial Powder; Intravenous Hospira Prescription ANDA: 202111 2022
Pemetrexed Disodium eq 100mg base/vial Powder; Intravenous Dr Reddys Prescription ANDA: 202596 2022
Pemetrexed Disodium eq 500mg base/vial Powder; Intravenous Dr Reddys Prescription ANDA: 202596 2022
Pemetrexed Disodium eq 1gm base/vial Powder; Intravenous Dr Reddys Prescription ANDA: 202596 2022
Pemetrexed Disodium eq 100mg base/vial Powder; Intravenous Accord Hlthcare Prescription ANDA: 203485 2022
Pemetrexed Disodium eq 500mg base/vial Powder; Intravenous Accord Hlthcare Prescription ANDA: 203485 2022
Pemetrexed Disodium eq 1gm base/vial Powder; Intravenous Accord Hlthcare Prescription ANDA: 203485 2022
Pemetrexed Disodium eq 100mg base/vial Powder; Intravenous Apotex Prescription ANDA: 203774 2022
Pemetrexed Disodium eq 500mg base/vial Powder; Intravenous Apotex Prescription ANDA: 203774 2022
Pemetrexed Disodium eq 100mg base/vial Powder; Intravenous Qilu Pharm Hainan Prescription ANDA: 204890 2022
Pemetrexed Disodium eq 500mg base/vial Powder; Intravenous Qilu Pharm Hainan Prescription ANDA: 204890 2022
Pemetrexed Disodium eq 100mg base/vial Powder; Intravenous Nang Kuang Pharm Co Prescription ANDA: 207352 2022
Pemetrexed Disodium eq 500mg base/vial Powder; Intravenous Nang Kuang Pharm Co Prescription ANDA: 207352 2022
Pemetrexed Disodium eq 100mg base/vial Powder; Intravenous Jiangsu Hansoh Pharm Prescription ANDA: 208696 2022
Pemetrexed Disodium eq 500mg base/vial Powder; Intravenous Jiangsu Hansoh Pharm Prescription ANDA: 208696 2022
Pemetrexed Disodium eq 1gm base/vial Powder; Intravenous Apotex Prescription ANDA: 209085 2022
Pemetrexed Disodium eq 750mg base/vial Powder; Intravenous Apotex Prescription ANDA: 209851 2022
Pemetrexed Disodium eq 1gm base/vial Powder; Intravenous Biocon Pharma Prescription ANDA: 211090 2022
Pemetrexed Disodium eq 100mg base/vial Powder; Intravenous Waverley Pharma Inc Prescription ANDA: 211899 2022
Pemetrexed Disodium eq 500mg base/vial Powder; Intravenous Waverley Pharma Inc Prescription ANDA: 211899 2022
Pemetrexed Disodium eq 100mg base/vial Powder; Intravenous Zydus Pharms Prescription ANDA: 214073 2022
Pemetrexed Disodium eq 500mg base/vial Powder; Intravenous Zydus Pharms Prescription ANDA: 214073 2022
Pemetrexed Disodium eq 1gm base/vial Powder; Intravenous Zydus Pharms Prescription ANDA: 214073 2022
Pemetrexed Disodium eq 100mg base/vial Powder; Intravenous Eugia Pharma Prescription ANDA: 214632 2022
Pemetrexed Disodium eq 500mg base/vial Powder; Intravenous Eugia Pharma Prescription ANDA: 214632 2022
Pemetrexed Disodium eq 1gm base/vial Powder; Intravenous Eugia Pharma Prescription ANDA: 214632 2022
Pemetrexed Disodium 100mg Injectable; Injection Dr Reddys Labs Inc Prescription NDA: 208297 2020
Pemetrexed Disodium 500mg Injectable; Injection Dr Reddys Labs Inc Prescription NDA: 208297 2020
Pemetrexed Disodium 1g Injectable; Injection Dr Reddys Labs Inc Prescription NDA: 208297 2020
Pemetrexed Disodium 500mg/20ml (25mg/ml) Solution; Intravenous Eagle Pharms Prescription NDA: 209472 2020
Pemetrexed Pfizer unknown Unknown Pfizer Europe Ma Eeig Withdrawn EMEA/H/C/004488 2017
Pemetrexed Medac 500 mg Powder For Solution; Intravenous Medac Gesellschaft Für Klinische Spezialpräparate Mbh Prescription EMEA/H/C/003905 2015
Ciambra 500 mg Powder For Solution; Intravenous Menarini International Operations Luxembourg S.A. Prescription EMEA/H/C/003788 2015
Pemetrexed Sandoz 500 mg Powder For Solution; Intravenous Sandoz Gmbh Prescription EMEA/H/C/004011 2015
Pemetrexed Accord 500 mg Powder For Solution; Intravenous Accord Healthcare S.L.U. Prescription EMEA/H/C/004072 2016
Pemetrexed Fresenius Kabi unknown Powder For Solution; Intravenous Fresenius Kabi Deutschland Gmbh Prescription EMEA/H/C/003895 2016
Pemetrexed Krka 500 mg Powder For Solution; Intravenous Krka D.D. Prescription EMEA/H/C/003958 2018
Pemetrexed Lilly unknown Unknown Eli Lilly Netherlands Withdrawn EMEA/H/C/004114 2015
Pemetrexed Hospira 500 mg Powder For Solution; Intravenous Pfizer Europe Ma Eeig Prescription EMEA/H/C/003970 2015
Alimta 500 mg Powder For Solution; Intravenous Eli Lilly Nederland B.V. Prescription EMEA/H/C/000564 2004
Armisarte 500 mg Concentrate For Solution; Intravenous Actavis Group Ptc Ehf Prescription EMEA/H/C/004109 2016
Act Pemetrexed 100 mg / vial Powder For Solution; Intravenous Actavis Pharma Company Cancelled DIN: 02428768 2018
Act Pemetrexed 500 mg / vial Powder For Solution; Intravenous Actavis Pharma Company Cancelled DIN: 02428776 2018
Act Pemetrexed 1000 mg / vial Powder For Solution; Intravenous Actavis Pharma Company Cancelled DIN: 02428784 2018
Alimta 500 mg / vial Powder For Solution; Intravenous Eli Lilly Canada Inc Cancelled DIN: 02253437 2004
Alimta 100 mg / vial Powder For Solution; Intravenous Eli Lilly Canada Inc Prescription DIN: 02306433 2009
Pemetrexed 100 mg / vial Powder For Solution; Intravenous Apotex Inc Prescription DIN: 02455498 2016
Pemetrexed 500 mg / vial Powder For Solution; Intravenous Apotex Inc Prescription DIN: 02455528 2016
Pemetrexed Disodium For Injection 500 mg / vial Powder For Solution; Intravenous Teva Canada Limited Prescription DIN: 02394227 2017
Pemetrexed Disodium For Injection 100 mg / vial Powder For Solution; Intravenous Pfizer Canada Ulc Prescription DIN: 02411016 2017
Pemetrexed Disodium For Injection 500 mg / vial Powder For Solution; Intravenous Pfizer Canada Ulc Prescription DIN: 02411024 2017
Pemetrexed Disodium For Injection 100 mg / vial Powder For Solution; Intravenous Accord Healthcare Inc Prescription DIN: 02438674 2017
Pemetrexed Disodium For Injection 500 mg / vial Powder For Solution; Intravenous Accord Healthcare Inc Prescription DIN: 02438682 2017
Pemetrexed Disodium For Injection 500 mg / vial Powder For Solution; Intravenous Mylan Pharmaceuticals Ulc Cancelled DIN: 02441616 2022
Pemetrexed Disodium For Injection 1000 mg / vial Powder For Solution; Intravenous Pfizer Canada Ulc Prescription DIN: 02442833 2017
Pemetrexed Disodium For Injection 100 mg / vial Powder For Solution; Intravenous Sandoz Canada Incorporated Cancelled DIN: 02454610 2019
Pemetrexed Disodium For Injection 500 mg / vial Powder For Solution; Intravenous Sandoz Canada Incorporated Cancelled DIN: 02454629 2019
Pemetrexed Disodium For Injection 1000 mg / vial Powder For Solution; Intravenous Sandoz Canada Incorporated Cancelled DIN: 02454637 2019
Pemetrexed Disodium For Injection 100 mg / vial Powder For Solution; Intravenous Teva Canada Limited Prescription DIN: 02459434 2017
Pemetrexed Disodium For Injection 500 mg / vial Powder For Solution; Intravenous Marcan Pharmaceuticals Inc Prescription DIN: 02472619 2018
Pemetrexed Disodium For Injection 100 mg / vial Powder For Solution; Intravenous Auro Pharma Inc Prescription DIN: 02517639 2021
Pemetrexed Disodium For Injection 500 mg / vial Powder For Solution; Intravenous Auro Pharma Inc Prescription DIN: 02517647 2021
Pemetrexed Disodium For Injection 1000 mg / vial Powder For Solution; Intravenous Auro Pharma Inc Prescription DIN: 02517655 2021
Pemetrexed Disodium For Injection 100 mg / vial Powder For Solution; Intravenous Marcan Pharmaceuticals Inc Prescription DIN: 02482967 2018
Pemetrexed For Injection 25 mg / ml Solution; Intravenous Accord Healthcare Inc Prescription DIN: 02515423 2022
Pemetrexed For Injection, Usp 100 mg / vial Powder For Solution; Intravenous Dr Reddy'S Laboratories Ltd Prescription DIN: 02463083 2022
Pemetrexed For Injection, Usp 500 mg / vial Powder For Solution; Intravenous Dr Reddy'S Laboratories Ltd Prescription DIN: 02463091 2022
Taro-Pemetrexed 100 mg / vial Powder For Solution; Intravenous Taro Pharmaceuticals Inc Prescription DIN: 02429195 2018
Taro-Pemetrexed 500 mg / vial Powder For Solution; Intravenous Taro Pharmaceuticals Inc Prescription DIN: 02429209 2017
Taro-Pemetrexed 1000 mg / vial Powder For Solution; Intravenous Taro Pharmaceuticals Inc Prescription DIN: 02480492 2021

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT03955042 Pilot Study of Pemetrexed for the Treatment of Chordoma Chordoma Phase 1 Treatment
NCT05209620 A Single Arm, Phase II Clinical Trial of Orelabrutinib Combined With Pemetrexed in the Treatment for Patients With Relapsed/Refractory Central Nervous System Lymphoma Central Nervous System Lymphoma Phase 2 Treatment
NCT02588781 Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study Colorectal Cancer Phase 2 Treatment
NCT03023319 Phase I Study of the Non-receptor Kinase Inhibitor Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors Carcinoma, Non-Small-Cell Lung; Mesothelioma; Bladder Cancer; Ovarian Cancer; Peritoneal Cancer; Thymoma; Thymus Cancer; Uterine Cervical Cancer Phase 1 Treatment
NCT00712062 Pilot Study to Determine Therapeutic Response of Pemetrexed (Alimta) in Recurrent or Progressive Primary Central Nervous System Lymphoma (PCNSL) by Establishing the Radiographic Response Rate Using Modified Macdonald Criteria Primary Central Nervous System Lymphoma Phase 2 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DCTPep is developed by Dr.Zheng's team.